Oxygenta Pharmaceutical Limited's board has approved the financial results for the quarter ended June 30, 2026. The company reported total revenue of ₹37.02 Cr and a net loss of ₹2.10 Cr for the quarter.

OP

Oxygenta Pharmaceutical Ltd524636 · Filed with the exchange

The board also appointed M/s. PCR & Associates as Cost Auditors for FY 2026-27 and re-constituted its POSH Committee.

The Annual General Meeting for FY 2025-26 is scheduled for August 21, 2026, via virtual means.

Additionally, during the quarter, the company availed financial assistance of ¥399 lakhs under the government's Emergency Credit Line Guarantee Scheme (ECLGS).

Read the original filing(PDF)

No comments yet. Be the first.

More from Oxygenta Pharmaceutical Ltd

All announcements

Others21-08-2026
AGM/EGM
Others21-08-2026
AGM/EGM
Important31-07-2026
Company Update
Others30-07-2026
AGM/EGM
Others30-07-2026
Others
Others30-07-2026
AGM/EGM

Free

Track this company, and every filing it makes

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

Create a free account

No card needed. Takes about a minute.